Myconostica, Ltd.
Myconostica Ltd. (“Myconostica”) is a spin-out from Manchester University (UK) that specialises in a new type of molecular diagnostic test for clinical use in fighting the growing problem of life-threatening invasive fungal infections. The market size is estimated to be in excess of US $500 million.
Myconostica is developing and commercialising a menu of real-time molecular diagnostic tests for life-threatening fungal infections. Over 10 million people are at risk of these infections each year in Europe and North America alone. A fundamental benefit of Myconostica’s tests is the fact that they are simple and can test for multiple fungi in a single process, thereby allowing much faster and more precise diagnosis. This in turn, can reduce mortality rates and allow more cost effective care by reducing intensive care stays and allowing more effective and targeted use of medications.
Amphion’s fully-diluted ownership stake in Myconostica was approximately 35.70% as of 31 December 2007, valued at US $5.8 million (2006: US $1.9 million).
Management
Jerel Whittingham – Chief Executive Officer
John Thornback Ph.D. – Chief Operations Officer
Prof. David Denning. – Research Director (CSO) and Founder
Nick Montague. – Finance Director (and co-Founder)
Arthur Bourne - Business Development Consultant
Board of Directors
Prof. David Denning, Chairman – Professor of Medicine and Medical Mycology, Manchester University
Richard C.E. Morgan – Chief Executive Officer, Amphion Innovations plc
John Thornback PhD – Chief Operations Officer, Myconostica Ltd.
Jerel Whittingham. – Chief Executive Officer, Myconostica Ltd. and Managing Director, Amphion Innovations UK Ltd.
